Axl-IN-18 (compound 25c) serves as a potent and selective Type II AXL inhibitor. It exhibits remarkable AXL inhibitory activity with an IC50 of 1.1 nM and is 343 times more selective for AXL compared to the closely related kinase MET, which has an IC50 of 377 nM. Axl-IN-18 significantly inhibits cell proliferation driven by AXL, reduces 4T1 cell migration and invasion in a dose-dependent manner, and induces apoptosis. In the BaF3/TEL-AXL xenograft model, Axl-IN-18 demonstrates significant antitumor efficacy.